Quantitative dynamic contrast-enhanced MR imaging can be used to predict the pathologic stages of oral tongue squamous cell carcinoma

Hong Deng,Xiaohui Duan,Ziliang Cheng,Shuqi Jiang,Na Guo,Zehong Yang,Jun Shen,Weike Zeng,Huijun Hu

doi:10.1186/s12880-020-00516-w

Abstract

BackgroundTo investigate whether quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic parameters can be used to predict the pathologic stages of oral tongue squamous cell carcinoma (OTSCC).MethodsFor this prospective study, DCE-MRI was performed in participants with OTSCC from May 2016 to June 2017. The pharmacokinetic parameters, including Ktrans, Kep, Ve, and Vp, were derived from DCE-MRI by utilizing a two-compartment extended Tofts model and a three-dimensional volume of interest. The postoperative pathologic stage was determined in each patient based on the 8th AJCC cancer staging manual. The quantitative DCE-MRI parameters were compared between stage I–II and stage III–IV lesions. Logistic regression analysis was used to determine independent predictors of tumor stages, followed by receiver operating characteristic (ROC) analysis to evaluate the predictive performance.ResultsThe mean Ktrans, Kep and Vp values were significantly lower in stage III–IV lesions compared with stage I–II lesions (p = 0.013, 0.005 and 0.011, respectively). Kep was an independent predictor for the advanced stages as determined by univariate and multivariate logistic analysis. ROC analysis showed that Kep had the highest predictive capability, with a sensitivity of 64.3%, a specificity of 82.6%, a positive predictive value of 81.8%, a negative predictive value of 65.5%, and an accuracy of 72.5%.ConclusionThe quantitative DCE-MRI parameter Kep can be used as a biomarker for predicting pathologic stages of OTSCC.

Highlights

To investigate whether quantitative dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) pharmacokinetic parameters can be used to predict the pathologic stages of oral tongue squamous cell carcinoma (OTSCC)
The purpose of this study was to determine the role of quantitative dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) in predicting the pathologic stages of OTSCC. Patients This prospective study was approved by the Ethics Committee of Sun Yat-Sen Memorial Hospital (Sun Yat-Sen University, Guangzhou, China), and written informed consent was obtained from all participants
Our study results showed that multiple pharmacokinetic parameters derived from qDCE-MRI were different between stage III–IV and stage I–II OTSCCs

Summary

Introduction

To investigate whether quantitative dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) pharmacokinetic parameters can be used to predict the pathologic stages of oral tongue squamous cell carcinoma (OTSCC). Oral tongue squamous cell carcinoma (OTSCC) is the most common malignancy of the oral cavity and comprises 25–40% of oral carcinomas [1]. It has a more aggressive clinical behavior and a relatively poor prognosis compared with other oral cavity and head and neck cancers [2]. The prognosis of OTSCC in early disease (TNM stage I–II) is better than that of advanced disease (TNM stage III–IV). [3], but it drops below 40% for those with advanced disease at the time of diagnosis [4]. Accurate staging of OTSCC prior to treatment is crucial for the treatment planning and prognosis prediction

Objectives

Methods

Results

Discussion

Conclusion